AR108500A1 - Un análogo de trifluoroetil quinolina específico para usar en el tratamiento de apds - Google Patents

Un análogo de trifluoroetil quinolina específico para usar en el tratamiento de apds

Info

Publication number
AR108500A1
AR108500A1 ARP170101315A ARP170101315A AR108500A1 AR 108500 A1 AR108500 A1 AR 108500A1 AR P170101315 A ARP170101315 A AR P170101315A AR P170101315 A ARP170101315 A AR P170101315A AR 108500 A1 AR108500 A1 AR 108500A1
Authority
AR
Argentina
Prior art keywords
apds
trifluoroethyl
treatment
analog
specific quinoline
Prior art date
Application number
ARP170101315A
Other languages
English (en)
Inventor
Duncan Philip Mhale
Andrew Charles Payne
Sven Kracker
Marina Cavazzana
Martin John Armstrong
Rodger Anthony Allen
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of AR108500A1 publication Critical patent/AR108500A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: N-{(R)-1-[8-cloro-2-(1-oxipiridin3-il)quinolin-3-il]-2,2,2-trifluoroetil}-pirido[3,2-d]pirimidin-4-ilamina, o una de sus sales farmacéuticamente aceptables, caracterizado porque es para usar en el tratamiento y/o prevención del síndrome de fosfoinositido 3-quinasa delta activado (APDS).
ARP170101315A 2016-05-19 2017-05-17 Un análogo de trifluoroetil quinolina específico para usar en el tratamiento de apds AR108500A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1608797.5A GB201608797D0 (en) 2016-05-19 2016-05-19 Therapeutic use

Publications (1)

Publication Number Publication Date
AR108500A1 true AR108500A1 (es) 2018-08-29

Family

ID=56369612

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101315A AR108500A1 (es) 2016-05-19 2017-05-17 Un análogo de trifluoroetil quinolina específico para usar en el tratamiento de apds

Country Status (18)

Country Link
US (1) US20190209567A1 (es)
EP (1) EP3458065A1 (es)
JP (1) JP2019516703A (es)
KR (1) KR20190009790A (es)
CN (1) CN109152783A (es)
AR (1) AR108500A1 (es)
AU (1) AU2017267172A1 (es)
BR (1) BR112018072450A2 (es)
CA (1) CA3023974A1 (es)
CL (1) CL2018003281A1 (es)
CO (1) CO2018013559A2 (es)
EA (1) EA201892638A1 (es)
GB (1) GB201608797D0 (es)
IL (1) IL262943A (es)
MX (1) MX2018013770A (es)
RU (1) RU2018144187A (es)
SG (1) SG11201809396SA (es)
WO (1) WO2017198590A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
WO2015117053A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
AU2016319116B2 (en) 2015-09-11 2020-10-01 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
SG10202007099TA (en) 2015-09-11 2020-08-28 Dana Farber Cancer Inst Inc Acetamide thienotriazoldiazepines and uses thereof
KR20180081809A (ko) 2015-11-25 2018-07-17 다나-파버 캔서 인스티튜트 인크. 2가 브로모도메인 억제제 및 그의 용도
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR082799A1 (es) * 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
MX2016014904A (es) * 2014-05-27 2017-02-28 Almirall Sa Sales de adicion de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)e til)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-car bonitrilo.

Also Published As

Publication number Publication date
EP3458065A1 (en) 2019-03-27
CA3023974A1 (en) 2017-11-23
IL262943A (en) 2018-12-31
AU2017267172A1 (en) 2018-12-13
MX2018013770A (es) 2019-03-21
BR112018072450A2 (pt) 2019-02-19
SG11201809396SA (en) 2018-11-29
RU2018144187A (ru) 2020-06-19
RU2018144187A3 (es) 2020-06-19
GB201608797D0 (en) 2016-07-06
JP2019516703A (ja) 2019-06-20
CL2018003281A1 (es) 2019-01-25
KR20190009790A (ko) 2019-01-29
US20190209567A1 (en) 2019-07-11
WO2017198590A1 (en) 2017-11-23
CN109152783A (zh) 2019-01-04
EA201892638A1 (ru) 2019-06-28
CO2018013559A2 (es) 2019-02-28

Similar Documents

Publication Publication Date Title
AR108500A1 (es) Un análogo de trifluoroetil quinolina específico para usar en el tratamiento de apds
IL288231A (en) An inhibitor of jak1/2 or a pharmaceutical salt derived from it and an inhibitor of pi3k or a pharmaceutical salt derived from it, for use in the treatment of myelofibroblasts.
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
UY36153A (es) ?inhibidores de la fosfoinosítido 3-quinasa delta para su uso en el tratamiento de una enfermedad cutánea inmunoampollosa mediada por autoanticuerpos?
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
HK1257584A1 (zh) 預防和治療系統性硬化症的藥物及其用途
MX2019005309A (es) Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico.
WO2017143115A3 (en) Enhancing the therapeutic activity of an immune checkpoint inhibitor
SI3452465T1 (sl) Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni
WO2015165980A3 (en) Treatment and prevention of alzheimer's disease (ad)
WO2015102000A3 (en) Ophthalmic viscosurgical device
WO2017129577A8 (en) Ophthalmic gabapentin for the treatment of corneal ulcers
EP3538083A4 (en) FORMULATIONS FOR THE TREATMENT OF EYE SURFACE DISEASES AND ASSOCIATED METHODS
CO2017010573A2 (es) Un análogo de trifluoroetil quinolina específico para uso en el tratamiento del síndrome de sjögren
EA201890122A1 (ru) Применение 2-(5s-метил-2-оксо-4r-фенилпирролидин-1-ил)ацетамида в лечении судорог
WO2015162552A3 (en) Composition for topic use
WO2016073652A8 (en) Iminosugars useful for the treatment of viral diseases
HK1257288A1 (zh) Pi3k的活性或功能的抑制劑用於治療原發性舍格倫綜合征的用途
TH1901000708A (th) องค์ประกอบและวิธีการยับยั้งmasp-3สำหรับการบำบัดของหลากหลายโรคและความผิดปกติ
EP3389649A4 (en) CONNECTION FOR THE TREATMENT AND / OR PREVENTION OF PARASITISED DISEASES
UA115417U (xx) Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі
TH1701007697A (th) ตัวยับยั้ง vmat2 สำหรับการบำบัดโรคหรือความผิดปกติทางประสาทวิทยา
TH1501005021A (th) การใช้อนุพันธ์ไพราโซโลไพริมิดีนสำหรับการรักษาความผิดปกติที่เกี่ยวข้องกับ pi3k (เดลตา)

Legal Events

Date Code Title Description
FB Suspension of granting procedure